Business
Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies
NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"NEEDHAM, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medical and scientific conferences. Candel President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci, and E. Antonio Chiocca, MD, PhD, FAANS, principal investigator for the CAN-3110 clinical trial, will present data and overviews pertaining to the company’s oncolytic viral immunotherapies at the 13th International Oncolytic Virus Conference. In addition, Patrick Y. Wen, MD, principal investigator, will present data on CAN-2409 from a phase 1 clinical trial in high-grade glioma at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO). Details are as follows: 13th International Oncolytic Virus Conference Meeting Date and Time: Friday, November 5, 2021, at 4:11 pm MT Presenter: E. Antonio Chiocca, MD, PhD, FAANS Oral Presentation Title: First in Human Clinical Trial of CAN-3110, An Oncolytic HSV Expressing ICP34.5, in Humans with Glioblastoma Session Title: Scientific Session 5: Clinical Trials 1 13th International Oncolytic Virus Conference Meeting Date and Time: Saturday, November 6, 2021, at 7:00 pm MT Presenter: Paul Peter Tak, MD, PhD, FMedSci Virtual Presentation Title: Leveraging Viral Oncolytic Immunotherapy Platform to Tip the Balance in Favor of the Immune System Session Title: Special Session 26th Annual Meeting of the Society for Neuro-Oncology (SNO) Date and Time: Friday, November 19, 2021, at 3:45 pm ET Presenter: Patrick Y. Wen, MD Oral Presentation Title: Phase 1 Clinical Trial of Oncolytic Viral Immunotherapy with CAN-2409 + Valacyclovir in Combination with Nivolumab and Standard of Care (SOC) in Newly Diagnosed High-Grade Glioma (HGG) Abstract Number: CTIM-13 Details from the presentations will be available on the Candel website at https://www.candeltx.com/news/. About CAN-2409 CAN-2409, Candel’s most advanced oncolytic viral immunotherapy candidate, is a replication-deficient adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the release of...